BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18790395)

  • 1. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.
    Eby PR; Partridge SC; White SW; Doot RK; Dunnwald LK; Schubert EK; Kurland BF; Lehman CD; Mankoff DA
    Acad Radiol; 2008 Oct; 15(10):1246-54. PubMed ID: 18790395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
    Partridge SC; Vanantwerp RK; Doot RK; Chai X; Kurland BF; Eby PR; Specht JM; Dunnwald LK; Schubert EK; Lehman CD; Mankoff DA
    J Magn Reson Imaging; 2010 Nov; 32(5):1124-31. PubMed ID: 21031518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
    Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM
    Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma.
    Kim TH; Yoon JK; Kang DK; Lee SJ; Jung YS; Yim H; An YS
    Ann Surg Oncol; 2015 Nov; 22(12):3866-72. PubMed ID: 25805237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast: a H2(15)O PET and 18F-FDG PET study.
    Hentschel M; Paulus T; Mix M; Moser E; Nitzsche EU; Brink I
    Nucl Med Commun; 2007 Oct; 28(10):789-97. PubMed ID: 17728609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor metabolism and perfusion ratio assessed by 18F-FDG PET/CT and DCE-MRI in breast cancer patients: Correlation with tumor subtype and histologic prognostic factors.
    An YS; Kang DK; Jung YS; Han S; Kim TH
    Eur J Radiol; 2015 Jul; 84(7):1365-70. PubMed ID: 25886700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of combined FDG-PET and dynamic contrast-enhanced CT of locally advanced cervical carcinoma before and during concurrent chemoradiotherapy suggests association between changes in tumor blood volume and treatment response.
    Banks TI; von Eyben R; Hristov D; Kidd EA
    Cancer Med; 2018 Aug; 7(8):3642-3651. PubMed ID: 29963760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow.
    de Langen AJ; van den Boogaart VE; Marcus JT; Lubberink M
    Oncologist; 2008 Jun; 13(6):631-44. PubMed ID: 18586918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI.
    Yoon H; Yoon D; Yun M; Choi JS; Park VY; Kim EK; Jeong J; Koo JS; Yoon JH; Moon HJ; Kim S; Kim MJ
    PLoS One; 2016; 11(7):e0159949. PubMed ID: 27459480
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Diwanji D; Onishi N; Hathi DK; Lawhn-Heath C; Kornak J; Li W; Guo R; Molina-Vega J; Seo Y; Flavell RR; Heditsian D; Brain S; Esserman LJ; Joe BN; Hylton NM; Jones EF; Ray KM
    Radiol Imaging Cancer; 2024 Mar; 6(2):e230082. PubMed ID: 38551406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.
    Niermann KJ; Fleischer AC; Huamani J; Yankeelov TE; Kim DW; Wilson WD; Hallahan DE
    J Ultrasound Med; 2007 Jun; 26(6):749-56. PubMed ID: 17526606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment.
    Tateishi U; Miyake M; Nagaoka T; Terauchi T; Kubota K; Kinoshita T; Daisaki H; Macapinlac HA
    Radiology; 2012 Apr; 263(1):53-63. PubMed ID: 22438441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multiparametric [
    Leithner D; Horvat JV; Bernard-Davila B; Helbich TH; Ochoa-Albiztegui RE; Martinez DF; Zhang M; Thakur SB; Wengert GJ; Staudenherz A; Jochelson MS; Morris EA; Baltzer PAT; Clauser P; Kapetas P; Pinker K
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1878-1888. PubMed ID: 31197455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.
    Cochet A; Pigeonnat S; Khoury B; Vrigneaud JM; Touzery C; Berriolo-Riedinger A; Dygai-Cochet I; Toubeau M; Humbert O; Coudert B; Fumoleau P; Arnould L; Brunotte F
    J Nucl Med; 2012 Apr; 53(4):512-20. PubMed ID: 22343501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
    J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic-flow relationships in primary breast cancer: feasibility of combined PET/dynamic contrast-enhanced CT.
    Groves AM; Wishart GC; Shastry M; Moyle P; Iddles S; Britton P; Gaskarth M; Warren RM; Ell PJ; Miles KA
    Eur J Nucl Med Mol Imaging; 2009 Mar; 36(3):416-21. PubMed ID: 18818917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.
    Tseng J; Dunnwald LK; Schubert EK; Link JM; Minoshima S; Muzi M; Mankoff DA
    J Nucl Med; 2004 Nov; 45(11):1829-37. PubMed ID: 15534051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.
    Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Charlop A; Lawton TJ; Schubert EK; Tseng J; Livingston RB
    J Nucl Med; 2002 Apr; 43(4):500-9. PubMed ID: 11937594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric functional MRI and
    Martens RM; Koopman T; Lavini C; Ali M; Peeters CFW; Noij DP; Zwezerijnen G; Marcus JT; Vergeer MR; Leemans CR; de Bree R; de Graaf P; Boellaard R; Castelijns JA
    Eur Radiol; 2021 Feb; 31(2):616-628. PubMed ID: 32851444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.